MOUNTAIN VIEW, Calif., Feb. 1 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases, today announced that it will present a company update at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference, which is being held February 6 - 8, 2007 at the Grand Hyatt Hotel in New York. Timothy S. Nelson, MAP Pharmaceuticals' President and CEO, will make the company's presentation on Tuesday, February 6, 2007, at 2:20 pm (EST).
About MAP Pharmaceuticals
Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases. The Company has two Phase 2 clinical development programs: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of an inhaled ergot alkaloid for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com .
MAP Pharmaceuticals, Inc.CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122, orljohnson@mappharma.com
Web site: http://www.mappharma.com/
